Latest Breaking News On - Astellas center - Page 1 : comparemela.com

Astellas Announces Data from ASPIRO Study in X-linked Myotubular Myopathy Published in The Lancet Neurology

Preliminary data analysis on ventilator dependence and motor improvement are reported alongside overall safety findings TOKYO, Nov. 15, 2023 /PRNewswire/ Astellas Pharma Inc. today announced.

University of california los angelesUnited statesSouth san franciscoSan franciscoRichard wilsonPerryb shiehNaoki okamuraPrnewswire astellas pharma incDrug administrationEuropean medicines agencyAstellas pharma incAstellas centerLancet neurologyCalifornia los angelesPrincipal investigatorSenior vice president

Astellas Announces Data from ASPIRO Study in X-linked Myotubular Myopathy Published in The Lancet Neurology

Astellas Announces Data from ASPIRO Study in X-linked Myotubular Myopathy Published in The Lancet Neurology
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

University of california los angelesUnited statesSan franciscoSouth san franciscoPerryb shiehRichard wilsonNaoki okamuraAstellas centerPrnewswire astellas pharma incEuropean medicines agencyDrug administrationAstellas pharma incThelancet neurologyCalifornia los angelesPrincipal investigatorSenior vice president

Astellas and Kate Therapeutics Announce Exclusive License Agreement for KT430

/PRNewswire/ Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas"), and Kate Therapeutics ("KateTx") today announced an exclusive.

San franciscoUnited statesSouth san franciscoAdam pearsonKevin forrestNaoki okamuraAstellas pharma incPrnewswire astellas pharma incAstellas centerKate therapeuticsChief strategy officerFocus area approachGene therapiesAstellas pharma inc

Astellas Announces Update on Preliminary Safety and Efficacy Data from FORTIS Study of Investigational AT845 in Adults with Late-Onset Pompe Disease

/PRNewswire/ Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced an update on preliminary safety and.

San franciscoUnited statesUnited kingdomSouth san franciscoKenji yasukawaAstellas pharma incFoundation trust at newcastle universityAstellas centerIsrael journal of medical sciencesAmerican college of medical geneticsPediatric researchAstellas pharmaNeuromuscular disordersHonorary consultant clinical geneticistNewcastle hospitalsNewcastle university

Astellas Announces Hold Lifted by FDA on FORTIS Clinical Trial of AT845 Investigational Treatment for Adult Patients with Late-Onset Pompe Disease

/PRNewswire/ Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced that the U.S. Food and Drug.

San franciscoUnited statesSouth san franciscoKenji yasukawaDrug administrationIsrael journal of medical sciencesPediatric researchAstellas pharma incAstellas centerPrnewswire astellas pharma incAmerican college of medical geneticsExecutive medical directorLate onset pompeLate onset pompe diseaseFocus area approachGene therapies